Microbiome-based biomarkers to guide personalized microbiome-

based therapies for Parkinson's disease.

Haydeh Payami* [1,2], Timothy R Sampson [2,3], Charles F Murchison [1,2,4], Zachary D Wallen [1,2]

[1] Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA

[2] Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,

MD, 20815, USA

[3] Department of Cell Biology, Emory University, Atlanta, GA, 30329, USA

[4] Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 35233,

USA

*Senior and Corresponding author:

Haydeh Payami, PhD

University of Alabama at Birmingham, Room 429, Civitan International Research Center, 1719

6th Ave S, Birmingham, AL 35233

Phone: 205-994-1909

Email: haydehpayami@uabmc.edu

Running title: Microbiome-based biomarkers

Word count: Abstract 191. Introduction 583. Method 1307. Results 616. Discussion 924.

35 references. 2 Tables. 3 Figures.

Abstract

We address an unmet challenge in Parkinson's disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. The gut microbiome is a new target for treatment of Parkinson's disease, with potential to halt disease progression. Our aim was to develop microbiome-based biomarkers to guide patient selection for microbiome-based clinical trials. We used microbial taxa that have been robustly associated with Parkinson's disease across studies and at high significance as dysbiotic features of Parkinson's disease. Using individual-level taxonomic relative abundance data, we classified patients according to their dysbiotic features, effectively defining microbiome-based subtypes of PD. We show that not all persons with Parkinson's disease have a dysbiotic microbiome, and not all dysbiotic Parkinson's disease microbiomes have the same features. Grounded in robust and reproducible data from differential abundance studies, we propose an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual's dysbiotic features. We demonstrate the method for Parkinson's disease. The concept, and the method, is generalizable for any disease with a microbiome component.

Introduction

Parkinson's disease (PD) is the fastest growing neurologic disease in the world [1]. PD is a progressively debilitating disease [2]. The earliest manifestations are often constipation, sleep disorder, and hyposmia, leading to the cardinal movement disorders, and as disease progresses, most patients develop psychosis and dementia. Treatments are symptomatic. There have been many clinical trials for disease modifying treatment aimed at stopping disease progression, and all have failed (clinicaltrials.gov). PD is a highly heterogenous disease. One treatment will not work for all patients. Biomarkers to guide selection of the right patients for the right drug has been a high-priority, unmet need.

It has long been known that constipation, inflammation in the gut, and permeable gut membrane are common in PD and precede motor signs [2]. Recent studies suggest some cases of PD start in the gut and spread to the brain, and in rodent models, PD pathologies are observed to spread

from gut to brain [3-7]. The gut origin raised the possibility that the gut microbiome could be

involved in the brain-gut-axis pathology of PD. A healthy gut microbiome controls metabolism of

drugs, toxicants and food, synthesis of vitamins and neurotransmitters, keeps the lining of the

gut intact, protects against pathogens, maintains the proper functioning of the immune and

nervous systems, and modulates brain-gut communication [8].

The gut microbiome is severely dysbiotic in PD, with characteristic features that are consistently

observed in large-scale high-resolution shotgun metagenomic studies and meta-analysis of

lower-resolution 16S studies [9-13]. Differential abundance analyses, conducted in different

geographic locations and with different methods, have converged on species and pathways that

are commonly dysbiotic in PD, among them are the following which we chose for the present

study: reduced levels of bacteria that degrade fiber and elevated levels of *Bifidobacterium*,

Lactobacillus, opportunistic pathogens (e.g., *Porphyromonas*), *Escherichia coli*, and certain

species of *Streptococcus* and *Actinomyces* [9-13]. Functional analyses of these data suggest

dysbiotic features of PD microbiome are relevant to multiple PD mechanisms, including

increased abundance of pathogens and immunogens, decreased production of neuroactive

molecules (dopamine, serotonin, glutamate and GABA), reduced capacity to degrade plant-

based fiber which leads to short chain fatty acids deficiency, increased inflammation and

compromised gut barrier, and elevated curli [9]. Curli is a bacterial amyloid produced by *E.coli*

which, in mice, induces alpha-synuclein aggregation, the hallmark of PD pathology [14,15]. Data

from genetic and toxicant-induced models of PD also suggest gut microbiome can trigger or

contribute to various PD pathologies and the manifestation of motor and non-motor phenotypes

[16-19], and that altering the microbiome via fecal microbiome transplantation (FMT)[20,21], antibiotics

treatments[22-25], or high fiber diet[26], each to some extent can reduce alpha-synuclein pathology,

inflammation, and motor and non-motor dysfunction.

The gut microbiome is an emerging target for PD therapies [27,28]. Results of early clinical trials

with fiber supplementation [29] and FMT [30-33] are promising. Next-generation targeted therapeutics

are forthcoming. One example (https://www.axialtx.com/our-programs/parkinsons-disease/) is a

small molecule that reduces curli and hence could potentially attenuate disease progression by

stopping curli-induced alpha-synuclein aggregation in the gut. The question is how to select

patients to optimize success of microbiome-based clinical trials. Do all PD patients have

elevated *E. coli* and curli? Is fiber supplementation sufficient to restore homeostasis to any

dysbiotic microbiome? Are all persons with PD candidates for FMT? Here, we show that not all

PD patients have a dysbiotic microbiome and not all dysbiotic microbiomes have the same

features. We introduce microbiome-based biomarkers to guide patient selection for clinical trials,

and upon success, as companion diagnostic for personalized treatment.

Method

Overview

We explored the possibility of subtyping PD patients based on the dysbiotic features of the

microbiome; and using the microbiome profile of an individual to gauge their suitability for

microbiome-based drug trials. The premise requires that disease associated features are

already well established, i.e., reproduced across studies, using multiple differential abundance

test methods controlling for confounders, at high statistical significance [9-13], and that the drug

targeting a feature has undergone proper pre-clinical processes. The present paper describes a

method to match patients to a treatment.

The overview of the method is shown in **Figure 1**. The concept and method are generalizable to

any disorder with a microbiome component with well-established dysbiotic features, here, we

focus on PD. The method requires a metagenomics reference dataset from a non-disease

population. The reference dataset should be from the same population as the patients to be

studied or treated (such reference datasets will soon be available for several populations). For

demonstration, we select several features of PD as potential targets for treatment. (In reality, the

feature can be a single gene or metabolite, a species, a cluster of related species, or multiple

polymicrobial clusters that a drug has been developed to target.) We then calculate the mean

relative abundance and confidence intervals (CI) of the features in the metagenomics dataset of

non-disease population. We have now created the reference dataset. We define dysbiosis by

setting thresholds for relative abundances in reference dataset (e.g., outside 95% CI). (We are

cognoscente that "normal" and dysbiotic" microbiome are yet to be defined. Here, we use a

working definition of dysbiotic to refer to abnormal levels of a well-established feature of PD

microbiome). Patients can now be screened for dysbiotic features, which entails obtaining a

stool sample, metagenomic sequencing and comparing the relative abundance of the features

in the patient to the reference dataset and the thresholds that define dysbiosis.

Species-level data and a step-by-step protocol to reproduce the current work are in the

Supplement as well as on ASAP-ZENODO Workplace (https://zenodo.org/records/11126860).

The source data we used is public, available for download as raw data from SRA or processed

data from Zenodo. Metagenomic sequences (raw data) are available at NCBI SRA under

BioProject ID PRJNA834801. The full taxonomic profiling data (processed data) is available at

Zenodo (https://zenodo.org/records/7246185).

Foundation of the method

Here, we use the data from the largest high-resolution metagenomic study of PD, published by

Wallen et al. [9]. The Wallen et al. study was compliant with all relevant ethical regulations and

was approved by Institutional Review Boards at University of Alabama at Birmingham and by

the Human Research Protection Office of United States Department of Defense (funding

agency). All subjects signed informed consent, including granting permission to share and use

their de-identified data in subsequent studies.

The dataset is composed of deep-shotgun next-generation metagenome sequences of microbial

DNA, extracted from stool samples of 490 individuals with PD and 234 neurologically healthy

controls (NHC). Each metagenome (data point) represents one sample taken from one

individual. Wallen et al. conducted differential abundance test via a metagenome-wide

association study (MWAS) and identified species, genes and pathways that are depleted or

overly abundant in PD. The feature we use here have been reproduced in other metagenomics

and meta-analyses [9-13]. We also conducted correlations network analysis and identified

polymicrobial clusters of species whose abundances grow or shrink together [9]. The visual of PD

microbiome in Wallen et al data is depicted in correlation network (**Figure 2**). Species are

plotted according to correlation in their abundances, forming clusters of correlated species,

using SparCC (RRID:SCR_022734, https://web.mit.edu/almlab/sparcc.html).

The concept

The published studies have been microbiome-centric, i.e., they identified dysbiotic features in

aggregates of patients as compared to controls. We now turn the approach around and make it

individual-centric, i.e., what does the microbiome of one patient look like? Is the microbiome

dysbiotic in every PD patient? Are all dysbiotic features present together, or are some features

present in a subset of patients, and if so, what percentage of patients has a given dysbiotic

feature? The answers to these questions are fundamental to any microbiome-based

therapeutic. To answer these questions, we had to (a) select features of interest that could

potentially be a target of treatment and (b) create an operational definition of dysbiosis. The

concept is generalizable to any disease and any microbiome in the body, and the method, both

feature selection and definition of dysbiosis, can be modified to accommodate study design.

Features of PD gut microbiome

For feature selection, we used the data reported in Wallen et al [9] and selected species that were

significantly associated with PD (i.e., their relative abundance was elevated or reduced in PD

not only in Wallen et al but reproduced across studies [9-13]), plus the cluster of rare opportunistic

pathogens were too rare to be tested individually but form a polymicrobial cluster that was

shown in two independent datasets to be elevated in PD [9,35]. We grouped the selected PD-

associated species into six features based on the correlation in their abundances ($|r|>0.2$,

$P<0.05$) and taxonomic relatedness (members of same genus). The six dysbiotic features

(**Table 1, Figure 2**) are as follows: (1) the cluster of opportunistic pathogens (elevated in PD),

(2) species of *Bifidobacteria* (elevated in PD), (3) species of *Lactobacillus* (elevated in PD), (4)

Streptococcus and *Actinomyces* species that are elevated in PD, (5) *E. coli* and *Klebsiella*

species that are elevated in PD, and (6) fiber-degrading bacteria (reduced in PD). There is more

to the dysbiosis of PD gut than these six features. Here, the aim being demonstrating the

method, we strived for a balance between minimizing complexity while capturing the most

robust and biologically relevant features.

Definition of dysbiotic and non-dysbiotic

Defining healthy and dysbiotic microbiome has been a challenge. For this project, we limited

the definition of dysbiotic to a metagenome that has very high or very low relative abundance of

a feature that is already well-established to be elevated or reduced in PD. To define very high

and very low, we set extreme thresholds to maximize the odds that the patient being enrolled in

trial is an optimal candidate. These thresholds can be changed to accommodate study design,

or relaxed when a drug is approved, and the biomarker becomes a companion diagnostic for

treatment.

For each feature, and per person, we calculated total relative abundance of each feature by

summing the relative abundances of the species within it. We then calculated the mean relative

abundance and its 95% CI in NHC (reference dataset). Next, we turned to individual-level PD

data. Considering each feature separately, we called a PD person's metagenome dysbiotic if the

relative abundance of the feature was outside the 95% CI of NHC. For features that are

elevated in PD in aggregate data, a PD individual's gut was called dysbiotic if the relative

abundance of the feature in that person was greater than the upper bound of 95% CI of NHC.

For the feature that is reduced in PD, a PD individual's microbiome was called dysbiotic if the

relative abundance of the feature in that person was less than the lower bound of 95% CI of

NHC (**Table 2**).

A key question was whether all individuals with PD have a dysbiotic gut microbiome. To answer

this question, we needed an operational definition of non-dysbiotic. We defined non-dysbiotic

per feature as being well within the norm of NHC range, i.e., below the mean of NHC if the

feature is elevated in PD, and above the mean if a feature is reduced in PD. When considering

all six features, a PD person was designated as not having a dysbiotic microbiome only if their

relative abundance for the five elevated features were all at or below the mean of NHC, and

their relative abundance for reduced fiber degrading feature was at or greater than the mean in

NHC.

Results

Not all PD metagenomes are dysbiotic, and not all dysbiotic microbiomes have the same

features.

In Wallen et al data, among the 490 individuals with PD studied, 392 (80%) had at least one

dysbiotic feature (**Figure 3a**). 98 (20%) did not have any dysbiotic feature defined as being

outside the 95% CI of NHC. Using the more cautious definition of non-dysbiotic, i.e. elevated

features being at or below the NHC mean and reduced features at or above the NHC mean, 76

(16%) of PD microbiomes were not dysbiotic. The patients without a dysbiotic microbiome can

be identified and excluded from microbiome-based therapeutics; doing so will boost power and

odds of success of clinical trials, and in clinical setting, will spare these patients unnecessary

trial and error in finding the right treatment.

Severe reduction in fiber-degrading bacteria was seen in 333 of 490 of PD patients (68%)

(**Figure 3a**). Among the 333 low fiber-degraders, only 96 had no other dysbiotic features

(**Figure 3b**), hence 71% (=(333-96)/333) of patients with low fiber-degraders had high levels of

at least one other dysbiotic feature. Thus, while deficiency of fiber degraders is very common,

only 20% (=96/490) of PD patients had low fiber-degraders as their sole feature. This suggests

that while fiber treatment would be beneficial for majority of patients, a subset would stand to

benefit the most from fiber, while others may need treatment for their other dysbiotic features as

well.

Features that are elevated in PD were found in subsets of patients: high levels of opportunistic

pathogens was detected in 66 (13%) of the 490 PD, *Bifidobacterium* in 161 (33%), *Lactobacillus*

in 103 (21%), *Streptococcus* and *Actinomyces* in 94 (19%), and *E. coli* and *Klebsiella* in 86

(18%). To demonstrate utility of the biomarker, consider *E. coli* which has been linked to

pathobiology of PD. *E. coli* encodes curli, an amyloid that induces alpha-synuclein aggregation

in mice [14,15]. Alpha-synuclein aggregation is a pathogenic hallmark of PD. Moreover, *E. coli* and

genes that encode and regulate curli production are elevated in PD gut [9]. A drug developed

against *E. coli* or curli will likely have a better odds of success in clinical trial if patients were

chosen from the 18% that have high levels of *E. coli* and curli.

There is some overlap across the groups shown in **Figure 3a**, because these features are not

mutually exclusive. For example, as shown in **Figure 3b**, among the 66 patients with high

opportunistic pathogens, 33 (50%) also had high *Bifidobacteria*, 15 (23%) had high

Lactobacillus, 18 (27%) had high *Streptococcus* and *Actinomyces*, 13 (20%) had *E. coli* and

Klebsiella, and 57 (86%) had low fiber degraders. These data suggest that at the present time,

with fiber and FMT being the only microbiome-based treatments, the most rational option for

treating the patients who have a severely dysbiotic microbiome is cleansing the microbiome with

antibiotics followed by FMT, excluding those without dysbiosis and those with only low fiber-

degraders. We are not advocating for FMT or any treatment modality per se, rather, pointing out

the utility of biomarkers in designing a study as well as choosing the patients to study and treat.

Application of the biomarker tool

Defining the features of interest and setting abundance thresholds to define dysbiotic/non-

dysbiotic in a healthy population will constitute the reference dataset for this biomarker tool. To

determine the composition of the metagenome of a patient will entail obtaining a stool sample,

extracting the DNA, sequencing, bioinformatic processing and taxonomic assignment of

sequences, and calculating relative abundances of the microbial features in the individual's

metagenome. The patient's relative abundances for the features of interest are then compared

to the reference dataset to determine if they are dysbiotic (**Figure 1**).

Discussion

Meta-analyses and large metagenomic studies have converged on certain microbial features

that consistently and significantly are altered in PD microbiome, independent of geography,

confounding covariates, and methodology. These well-established disease-associated taxa are

pre-requisite to, and the foundation of biomarkers described here. Here, we used these robust

associations to define subtypes of PD based on dysbiotic features of microbiome. We

introduced a microbiome-based biomarker tool to guide patient selection for clinical trials and to

serve as companion diagnostic for personalized treatments. With this tool, we can "see" if and

what is dysbiotic in an individual and act accordingly. The method is applicable for any patient at

any stage of disease. The tool can be easily modified (by redefining features and adjusting

thresholds) as the field advances, and to meet varying needs of different studies. Here, we

demonstrated the development and the potential utility of the tool for identifying subtypes of PD

based on their microbiome features. The concept is generalizable to any disease with a

microbiome component.

Treating a dysbiotic microbiome can potentially be disease modifying, which has been an

elusive goal in PD field. Functional inference of human data and experiments in mice indicate

dysbiotic features of PD microbiome contribute to several disease mechanisms, including alpha-

synuclein aggregation which is at the core of PD pathology, disrupted neuro-signaling, and

inflammation [9,15,16]. It is therefore reasonable to work towards microbiome-based therapies that

could halt disease progression. As we learn which features are causal and which result from

disease (an active area of research), microbiome-based biomarkers will be useful for identifying

pathogenic dysbiosis early to prevent disease before onset.

Microbiome-based treatments under consideration for PD include prebiotics (e.g., fiber

supplements), probiotics (beneficial bacteria packaged and marketed direct to consumer), FMT,

and next generation therapeutics that are targeted to a specific feature (e.g., small molecules,

phage, CRSPR-Cas9). The microbiome-based biomarkers described here can serve as

companion diagnostic for all treatment modalities. Take fiber supplementation for example,

which is safe and likely beneficial for everyone. We show here that indeed, the majority of PD

patients have severely depleted levels of fiber-degrading bacteria. Increasing fiber intake is

effectively feeding these bacteria and causing them to grow and multiply, and it has shown

promise in an early clinical trial with newly diagnosed PD patients [29]. The value of coupling

biomarkers with fiber treatment is in identifying patients who, in addition to being low on fiber-

degraders, have elevated levels of harmful pathogenic bacteria, which is an important

consideration both for patient selections for clinical trials and for treating the individuals. As for

probiotics on the market, most are composed of "beneficial" species of *Bifidobacteria* and/or

Lactobacillus, which ironically, are highly elevated in PD. The value of the biomarker in this case

is to avoid supplementation that is counter indicated. FMT is showing promise for PD [30], but it

carries risks concerning safety and compatibility of donor sample with host environment. Using

biomarkers, unnecessary FMT can be avoided, sparing the patients who do not have a dysbiotic

microbiome and those whose only problem is low fiber-degraders. Targeted treatments could

replace the need for FMT, and they too would benefit from a companion diagnostic. For

example, for a treatment targeted to abolish the opportunistic pathogens, the biomarker can

identify the 13% of patients who would be the best candidates.

Currently, we do not know if alleviating one dysbiotic feature would restore homeostasis to the

rest of the microbiome, and what that central feature might be. Consumption of fiber is the

safest and simplest treatment. In a clinical trial performed on 20 newly diagnosed PD patients,

treatment with fiber increased the abundance of fiber-degrading bacteria and production of short

chain fatty acids and resulted in shifts in the microbiome community [29]. Fiber-degrading species

are in the center of the correlation network with tight positive and negative correlations to

several PD-associated species (**Figure 2**). It is therefore plausible that fiber treatment, aimed to

increase the abundance of fiber-degrading bacteria, may restore equilibrium to PD-associated

species that map to the center of network and are either positively or negatively correlated with

fiber-degraders. However, while possible, it is less likely that fiber treatment alone would

eliminate overabundance of opportunistic pathogens, for example, considering that opportunistic

pathogens are a dense isolated cluster with no connection to fiber-degrading species.

Profiling the patients' metagenome and comparing them to the reference dataset will show

where they fall in the spectrum of dysbiosis. This concept, and the proposed method, holds true

regardless of feature, disease, or dataset. However, the relative abundances of the features and

therefore the range and thresholds for defining dysbiosis may differ across populations. Hence,

it is important that the reference dataset is from the same source population as patients. Here,

we used a cohort of neurologically healthy older adults from Birmingham, Alabama in United

States for our reference dataset, as our patients are also from Birmingham. There are regional

variation in microbiome, reflecting cultural, dietary, socioeconomic, and geographic influences.

Despite regional variations, the main PD-associated features are robust and reproducible

[9,11,12,35]. Even so, the relative abundances, and hence the thresholds for defining dysbiosis, may

still vary across populations. Not every investigator can amass hundreds of controls to

investigate population-specific abundances to set their thresholds. This impediment will be

overcome soon by current efforts to collect all data generated and made public. These

collaborative global efforts are aimed at meta-analyses, a by-product of which will be open-

access to well-curated datasets from across the world that can be used as reference datasets to

generate population-specific thresholds for biomarkers and companion diagnostics.

Data availability

The dataset used for biomarker development is publicly available, open access with no

restrictions, as described in detail in Wallen et al 2022 [9]. The dataset is available on

two repositories to enable the investigators to download the data in either the raw or

processed form. The raw metagenomic sequences and accompanying metadata are on NCBI

SRA under BioProject ID PRJNA834801 [https://www.ncbi.nlm.nih.gov/bioproject/834801]. The

post-QC and post taxonomic profiling data are on Zenodo [https://zenodo.org/record/7246185].

Here we used species-level data (presented in Supplement) that was extracted from the

taxonomic profiling data downloaded from Zenodo in January 2024.

Code and software

Algorithm was developed using Microsoft Excel v.16.84 (RRID:SCR_016137)

https://www.microsoft.com/en-gb/. Numbers were double checked using R v4.3.3.

(RRID:SCR_001905) https://www.r-project.org/. Both Excel and R code are provided in the

Supplement, as well as in ASAP-ZENODO Workplace (https://zenodo.org/records/11126860).

Acknowledgements

This work was supported by The Strain Endowed Chair in Parkinson's Disease to the University

of Alabama at Birmingham (HP) and Aligning Science Across Parkinson's [ASAP-020527]

through the Michael J. Fox Foundation for Parkinson's Research (MJFF) (HP, TRS, CFM,

ZDW). For the purpose of open access, the authors have applied a CC BY public copyright

license to all Author Accepted Manuscripts arising from this submission. Opinions,

interpretations, conclusions, and recommendations are those of the authors and are not

necessarily endorsed by the funding agencies.

Author contribution

This is a collaborative team (genomics (HP), microbiology (TRS), statistics (CFM),

bioinformatics (ZDW)). The lead/corresponding author (HP) conceptualized and developed the

method. HP drafted the manuscript and all authors contributed to revision and approved the

final version.

Competing interest

HP has intellectual property pending on Personalized Microbiome-Based Therapies, Serial No.:

63/571,787; Filing Date: March 29, 2024. TRS is a co-inventor on intellectual property related

to a small molecule microbiome-based therapy - US Patent 11,707,493 and 11,147, 792.

References

1   Collaborators, G. B. D. P. s. D. Global, regional, and national burden of Parkinson's

disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Lancet Neurol **17**, 939-953 (2018). https://doi.org/10.1016/S1474-4422(18)30295-3

2   Obeso, J. A. *et al.* Past, present, and future of Parkinson's disease: A special essay on

the 200th Anniversary of the Shaking Palsy. *Mov Disord* **32**, 1264-1310 (2017).

https://doi.org/10.1002/mds.27115

3   Braak, H., Rub, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson's disease: possible

routes by which vulnerable neuronal types may be subject to neuroinvasion by an

unknown pathogen. *J Neural Transm (Vienna)* **110**, 517-536 (2003).

https://doi.org/10.1007/s00702-002-0808-2

4   Horsager, J. *et al.* Brain-first versus body-first Parkinson's disease: a multimodal imaging

case-control study. *Brain* **143**, 3077-3088 (2020). https://doi.org/10.1093/brain/awaa238

5   Holmqvist, S. *et al.* Direct evidence of Parkinson pathology spread from the

gastrointestinal tract to the brain in rats. *Acta Neuropathol* **128**, 805-820 (2014).

https://doi.org/10.1007/s00401-014-1343-6

6   Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-

synuclein pathology: Vagal highway or dead end? *Mov Disord* **34**, 307-316 (2019).

https://doi.org/10.1002/mds.27556

7   Kim, S. *et al.* Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to

the Brain Models Parkinson's Disease. *Neuron* **103**, 627-641 e627 (2019).

https://doi.org/10.1016/j.neuron.2019.05.035

8   Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. *Nat Rev*

Microbiol **19**, 55-71 (2021). https://doi.org/10.1038/s41579-020-0433-9

9   Wallen, Z. D. *et al.* Metagenomics of Parkinson's disease implicates the gut microbiome

in multiple disease mechanisms. *Nat Commun* **13**, 6958 (2022).

https://doi.org/10.1038/s41467-022-34667-x

10   Palacios, N. *et al.* Metagenomics of the Gut Microbiome in Parkinson's Disease:

Prodromal Changes. *Ann Neurol* **94**, 486-501 (2023). https://doi.org/10.1002/ana.26719

11   Romano, S. *et al.* Meta-analysis of the Parkinson's disease gut microbiome suggests

alterations linked to intestinal inflammation. *NPJ Parkinsons Dis* **7**, 27 (2021).

https://doi.org/10.1038/s41531-021-00156-z

12   Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-

analysis. *Parkinsonism Relat Disord* **94**, 1-9 (2022).

https://doi.org/10.1016/j.parkreldis.2021.11.017

13   Boktor, J. C. *et al.* Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut

Metagenome. *Mov Disord* **38**, 399-409 (2023). https://doi.org/10.1002/mds.29300

14   Chen, S. G. *et al.* Exposure to the Functional Bacterial Amyloid Protein Curli Enhances

Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. *Sci*

Rep **6**, 34477 (2016). https://doi.org/10.1038/srep34477

15   Sampson, T. R. *et al.* A gut bacterial amyloid promotes alpha-synuclein aggregation and

motor impairment in mice. *Elife* **9** (2020). https://doi.org/10.7554/eLife.53111

16   Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a

Model of Parkinson's Disease. *Cell* **167**, 1469-1480 e1412 (2016).

https://doi.org/10.1016/j.cell.2016.11.018

17   Matheoud, D. *et al.* Intestinal infection triggers Parkinson's disease-like symptoms in

Pink1(-/-) mice. *Nature* **571**, 565-569 (2019). https://doi.org/10.1038/s41586-019-1405-y

18   Radisavljevic, N. *et al.* Effects of Gut Microbiota Alterations on Motor, Gastrointestinal,

and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. *J Parkinsons Dis*

12, 1479-1495 (2022). https://doi.org/10.3233/JPD-223165

19   Bhattarai, Y. *et al.* Role of gut microbiota in regulating gastrointestinal dysfunction and
motor symptoms in a mouse model of Parkinson's disease. *Gut Microbes* **13**, 1866974
(2021). https://doi.org/10.1080/19490976.2020.1866974

20   Sun, M. F. *et al.* Neuroprotective effects of fecal microbiota transplantation on MPTP-
induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha
signaling pathway. *Brain Behav Immun* **70**, 48-60 (2018).
https://doi.org/10.1016/j.bbi.2018.02.005

21   Zhao, Z. *et al.* Fecal microbiota transplantation protects rotenone-induced Parkinson's
disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4
signaling pathway through the microbiota-gut-brain axis. *Microbiome* **9**, 226 (2021).
https://doi.org/10.1186/s40168-021-01107-9

22   Bisht, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral
oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
Neurotoxicology **44**, 71-79 (2014). https://doi.org/10.1016/j.neuro.2014.05.009

23   Du, Y. *et al.* Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the
MPTP model of Parkinson's disease. *Proc Natl Acad Sci U S A* **98**, 14669-14674 (2001).
https://doi.org/10.1073/pnas.251341998

24   Pu, Y. *et al.* Antibiotic-induced microbiome depletion protects against MPTP-induced
dopaminergic neurotoxicity in the brain. *Aging (Albany NY)* **11**, 6915-6929 (2019).
https://doi.org/10.18632/aging.102221

25   Kaur, B. & Prakash, A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation
and restores BDNF in MPTP model of Parkinson's disease in rats. *Pathophysiology* **24**,
71-79 (2017). https://doi.org/10.1016/j.pathophys.2017.02.001

26   Abdel-Haq, R. *et al.* A prebiotic diet modulates microglial states and motor deficits in
alpha-synuclein overexpressing mice. *Elife* **11** (2022).
https://doi.org/10.7554/eLife.81453

27   Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. *Nat Rev Microbiol* **20**,
365-380 (2022). https://doi.org/10.1038/s41579-021-00667-9

28   Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease -
from basic research to the clinic. *Nat Rev Neurol* **18**, 476-495 (2022).
https://doi.org/10.1038/s41582-022-00681-2

29   Hall, D. A. *et al.* An open label, non-randomized study assessing a prebiotic fiber
intervention in a small cohort of Parkinson's disease participants. *Nat Commun* **14**, 926
(2023). https://doi.org/10.1038/s41467-023-36497-x

30   DuPont, H. L. *et al.* Fecal microbiota transplantation in Parkinson's disease-A

randomized repeat-dose, placebo-controlled clinical pilot study. *Front Neurol* **14**,

1104759 (2023). https://doi.org/10.3389/fneur.2023.1104759

31   Cheng, Y. *et al.* Efficacy of fecal microbiota transplantation in patients with Parkinson's

disease: clinical trial results from a randomized, placebo-controlled design. *Gut Microbes*

15, 2284247 (2023). https://doi.org/10.1080/19490976.2023.2284247

32   Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota

transplant as a potential treatment for Parkinson's disease - A case series. *Clin Neurol*

Neurosurg **207**, 106791 (2021). https://doi.org/10.1016/j.clineuro.2021.106791

33   Xue, L. J. *et al.* Fecal microbiota transplantation therapy for Parkinson's disease: A

preliminary study. *Medicine (Baltimore)* **99**, e22035 (2020).

https://doi.org/10.1097/MD.0000000000022035

34   . (!!! INVALID CITATION !!! 9).

35   Wallen, Z. D. *et al.* Characterizing dysbiosis of gut microbiome in PD: evidence for

overabundance of opportunistic pathogens. *NPJ Parkinsons Dis* **6**, 11 (2020).

https://doi.org/10.1038/s41531-020-0112-6

Table 1. Six main dysbiotic features of PD gut microbiome

Feature	Species composition of feature	PD association	Number of connections
Opp pathogens	*Actinomyces turicensis*	Increased as cluster	8
Opp pathogens	*Anaerococcus octavius*	Increased as cluster	4
Opp pathogens	*Anaerococcus vaginalis*	Increased as cluster	5
Opp pathogens	*Atopobium minutum*	Increased as cluster	8
Opp pathogens	*Corynebacterium amycolatum*	Increased as cluster	2
Opp pathogens	*Corynebacterium aurimucosum*	Increased as cluster	2
Opp pathogens	*Finegoldia magna*	Increased as cluster	7
Opp pathogens	*Gemella asaccharolytica*	Increased as cluster	2
Opp pathogens	*Peptoniphilus harei*	Increased as cluster	1
Opp pathogens	*Peptoniphilus lacrimalis*	Increased as cluster	3
Opp pathogens	*Peptoniphilus sp HMSC062D09*	Increased as cluster	7
Opp pathogens	*Porphyromonas asaccharolytica*	Increased	6
Opp pathogens	*Porphyromonas sp HMSC065F10*	Increased as cluster	11
Opp pathogens	*Porphyromonas uenonis*	Increased as cluster	6
Opp pathogens	*Prevotella bergensis*	Increased as cluster	1
Opp pathogens	*Prevotella buccalis*	Increased as cluster	10
Opp pathogens	*Prevotella disiens*	Increased as cluster	1
Opp pathogens	*Prevotella timonensis*	Increased as cluster	8
Opp pathogens	*Varibaculum cambriense*	Increased as cluster	10
Bifidobacteria	*Bifidobacterium dentium*	Increased	12
Bifidobacteria	*Bifidobacterium bifidum*	Increased	3
Bifidobacteria	*Bifidobacterium breve*	Increased	24
Bifidobacteria	*Bifidobacterium gallinarum*	Increased	14
Bifidobacteria	*Bifidobacterium longum*	Increased	5
Bifidobacteria	*Bifidobacterium pullorum*	Increased	12
Bifidobacteria	*Bifidobacterium saeculare*	Increased	13
Lactobacillus	*Lactobacillus fermentum*	Increased	14
Lactobacillus	*Lactobacillus gasseri*	Increased	10
Lactobacillus	*Lactobacillus paragasseri*	Increased	9
Lactobacillus	*Lactobacillus salivarius*	Increased	9
Lactobacillus	*Lactobacillus reuteri*	Increased	1
Lactobacillus	*Lactobacillus rhamnosus*	Increased	11
Strepto / Actino	*Actinomyces naeslundii*	Increased	4
Strepto / Actino	*Actinomyces oris*	Increased	16
Strepto / Actino	*Actinomyces sp HPA0247*	Increased	3
Strepto / Actino	*Actinomyces sp oral taxon 448*	Increased	3
Strepto / Actino	*Streptococcus anginosus group*	Increased	10

Strepto / Actino	*Streptococcus mutans*	Increased	13
Strepto / Actino	*Streptococcus vestibularis*	Increased	15
Strepto / Actino	*Streptococcus lutetiensis*	Increased	3
E. coli / klebsiella	*Escherichia coli*	Increased	5
E. coli / klebsiella	*Klebsiella pneumoniae*	Increased	3
E. coli / klebsiella	*Klebsiella quasipneumoniae*	Increased	3
Fiber-degraders	*Blautia wexlerae*	Decreased	17
Fiber-degraders	*Blautia hansenii*	Decreased	17
Fiber-degraders	*Anaerostipes hadrus*	Decreased	48
Fiber-degraders	*Clostridium sp CAG 58*	Decreased	27
Fiber-degraders	*Eubacterium eligens*	Decreased	47
Fiber-degraders	*Eubacterium hallii*	Decreased	52
Fiber-degraders	*Eubacterium ramulus*	Decreased	25
Fiber-degraders	*Eubacterium rectale*	Decreased	21
Fiber-degraders	*Eubacterium sp CAG 38*	Decreased	22
Fiber-degraders	*Faecalibacterium prausnitzii*	Decreased	59
Fiber-degraders	*Fusicatenibacter saccharivorans*	Decreased	45
Fiber-degraders	*Roseburia faecis*	Decreased	21
Fiber-degraders	*Roseburia intestinalis*	Decreased	21
Fiber-degraders	*Roseburia inulinivorans*	Decreased	27
Fiber-degraders	*Ruminococcus bicirculans*	Decreased	33
Fiber-degraders	*Ruminococcus lactaris*	Decreased	12

We selected species that individually, or as a cluster, were significantly elevated or reduced in PD [9-13], and assigned them to a "feature" according to the correlation in their abundances (connectivity, see **Figure 2**) and their taxonomic relatedness (members of same genus). Here, our aim was to demonstrate the method, for which we strived for a balance between capturing the most robust association with PD and reducing the complexity. Features can be redefined to accommodate the aims of the investigation.

Table 2. **A working definition of dysbiotic for identifying microbiome-based subtypes of PD**

Feature	Relative abundance of feature in 234 NHC			Relative abundance of feature in 490 PD			N among 490 PD outside 95% CI of NHC
	Mean	Upper 95% CI	Lower 95% CI	Mean	Upper 95% CI	Lower 95% CI	
Opp. pathogens	0.01%	**0.01%**	0.00%	0.10%	0.20%	0.00%	66 (13%)
Bifidobacteria	2.06%	**2.66%**	1.47%	5.07%	5.98%	4.17%	161 (33%)
Lactobacillus	0.11%	**0.19%**	0.04%	0.55%	0.74%	0.36%	103 (21%)
Streptococcus / Actinomyces	0.19%	**0.33%**	0.06%	0.39%	0.54%	0.25%	94 (19%)
E. coli / Klebsiella	1.47%	**2.23%**	0.72%	1.94%	2.44%	1.43%	86 (18%)
Fiber-degraders	22.35%	23.88%	**20.81%**	15.29%	16.36%	14.22%	333 (68%)

In this context, the term dysbiotic refers to a microbiome in which the relative abundance of a well-established PD-associated feature is very high (for features that are elevated in PD) or very low (if reduced in PD). Here, each feature is composed of several PD-associated species, as shown in **Table 1**. The relative abundance of each species in each individual was calculated as reported before [9] and can be found here https://zenodo.org/record/7246185. We calculated relative abundance of each feature in each neurologically healthy control (NHC) and individual with PD by summing the relative abundances of the species within the feature for that individual. We then calculated the mean and 95% confidence interval (CI) of the mean in the NHC and PD separately. We set the threshold for defining dysbiotic at the upper 95% CI of NHC for features that are elevated in PD, and at lower 95% CI of NHC for fiber-degraders that are reduced in PD. Last column is the number of PD patients, among 490 total, who were called dysbiotic for each feature. For example, in 161 of 490 PD patients, the relative abundance of *Bifidobacteria* was higher than 2.66% which was the upper 95% CI limit of NHC. Similarly, in 333 of 490 patients, the relative abundance of fiber-degrading bacteria was lower than 20.81% which was the lower 95% CI limit in NHC. See Figure 3 for overlaps.

Building the reference dataset

No Disease

Sample collection for microbial
DNA extraction

Metagenomic sequencing

Taxonomic assignment

Relative abundance of species (columns)
per individual (rows)

Relative abundances
Range, mean
95% CI in
No Disease population

Application

compare

Relative
abundances

Figure 1. The method.

For Parkinson's disease, several disease-associated microbial features have already been well established, i.e., reproduced across studies at high statistical significance using multiple differential abundance test methods and including covariates and confounders [9-13]. Clinical trials of microbiome-based treatments are underway. The present paper describes a method to match patients to treatments, excluding patients who do not have the feature of interest, and enriching the trial with patients with high abundance of the feature being targeted.

A reference dataset is built by obtaining the metagenomic profiles of a non-disease cohort that represents the same population as the persons to be studied or treated. Once this infrastructure is in place, one can pick any feature (from a microbial gene to species to polymicrobial clusters), calculate its relative abundance and confidence interval (CI) in the non-disease group, and set thresholds for defining dysbiotic and non-dysbiotic. Application entails obtaining the metagenomic profile of the individual of interest and comparing it to the non-disease population. Here, we selected 6 PD-associated features (each a polymicrobial cluster), 5 of which are elevated in PD, and one reduced in PD [9]. We set the threshold at 95%CI of the non-disease reference dataset. A person would be marked as dysbiotic for a feature if their relative abundance of that feature is above (for features that are elevated in PD) or below (for feature that are reduced) the 95%CI in non-disease population.

Figure 2. Polymicrobial clusters of species in PD gut microbiome.

Pairwise correlation in relative abundances of all species detected in 490 unique PD gut metagenomes (i.e. 490 individuals with PD) was calculated and plotted (methods are described in Wallen et al [9]). Each circle (node) represents one species and the curved lines (edges) connect species whose relative abundance correlate with each other (at correlation |r|>0.2, permuted P<0.05). Here, we have highlighted PD-associated species that were selected for this study, denoting by color the 6 dysbiotic features (species within each feature are listed in **Table 1**):

Blue: Opportunistic pathogens (elevated in PD)

Red: fiber-degraders (reduced in PD)

Yellow: *E. coli* and *Klebsiella* (elevated in PD)

Green: *Bifidobacteria* (elevated in PD)

Orange: *Lactobacillus* (elevated in PD)

Purple: *Streptococcus* and *Actinomyces* (elevated in PD)

Grey: associated with PD, not selected as feature

Empty circle: not associated with PD

a

Individuals with PD in a clinic setting.

N=490

Elevated Opp. pathogens	Elevated *Bifidobacteria*	Elevated *Lactobacillus*	Elevated *Strepto / Actino*	Elevated *E. coli / Klebsiella*	Reduced fiber degraders	No detectable dysbiosis
N=66	N=161	N=103	N=94	N=86	N=333	N=98 (20%)
13%	33%	21%	19%	18%	68%	N=76 (16%)

b

	Opp path	*Bifido-bacteria*	*Lacto-bacillus*	*Strepto /Actino*	*E. coli / Klebsiella*	Fiber-degraders
Opp Pathogens	66					
Bifidobacteria	33	161				
Lactobacillus	15	49	103			
Strepto / Actino	18	50	47	94		
E. coli/ Klebsiella	13	27	27	22	86	
Fiber-Degraders	57	135	88	81	69	333
No Others	5	18	5	5	9	96

c

Figure 3. Subtyping PD by the dysbiotic features of the gut microbiome.

The total number of patients is 490. The total number of patients with a dysbiotic feature is 392 (=490-98). The number of patients with a given dysbiotic feature are given in a-c. Actual numbers are given so that percentages can be calculated with the desired denominator.

(a) Proportion of PD patients with different dysbiotic features.

- Elevated features: number of PD persons, among the 490, who had an abundance higher than upper limit of the 95% CI of the abundance in neurologically healthy control (NHC).

- Reduced feature: number of PD persons, among the 490, who had an abundance lower than the lower limit of 95% CI of the abundance in NHC.

- No detectable dysbiosis: 98 of 490 (20%) did not fall outside 95% CI of NHC for any feature. 76 of 490 (16%) of PD persons fit the more cautious definition of non-dysbiotic, whose abundances for every elevated feature (opportunistic pathogens, *Bifidobacteria*, *Lactobacillus*, *Streptococcus* and *Actinomyces* (Strepto/Actino), and *E. coli/Klebsiella*) was below the NHC mean, and their abundance for reduced fiber-degrading bacteria was above the NHC mean.

(b) Pairwise overlap in features, n=number of patients, from 490, who have the two specified features. The total for six features (the diagonal) is 843, nearly double the number of 490 subjects, because features do co-occur in an individual. For example, 66 of 490 subjects had elevated (>95%CI of NHC) levels of opportunistic pathogens, among them, 33 (50%) also had elevated Bifidobacteria. Or the example in the text, 71% (=(333-96)/333) of low fiber-degraders had high level of at least one other feature.

(c) Overlap across the 5 features that are elevated in PD (fiber-reducers not included for legibility). For example, 19 subjects have elevated levels (>95%CI of NHC) of *Streptococcus* and *Actinomyces* only, another 2 subjects have high *Streptococcus* and *Actinomyces* and high opportunistic pathogens, another 3 have high *Streptococcus* and *Actinomyces,* high opportunistic pathogens, and high *Lactobacillus*, etc.